ANVISA APPROVES THE FIRST BIOSIMILAR MONOCLONAL ANTIBODY BASED ON COMPARABILITY IN BRAZIL

Arq Gastroenterol. 2016 Apr-Jun;53(2):60-1. doi: 10.1590/S0004-28032016000200002.
No abstract available

Publication types

  • Comparative Study
  • Letter

MeSH terms

  • Antibodies, Monoclonal*
  • Biosimilar Pharmaceuticals*
  • Brazil
  • Drug Approval*
  • Gastrointestinal Agents*
  • Government Agencies
  • Humans
  • Inflammatory Bowel Diseases
  • Infliximab*

Substances

  • Antibodies, Monoclonal
  • Biosimilar Pharmaceuticals
  • CT-P13
  • Gastrointestinal Agents
  • Infliximab